Patent Application
20170362635
The present disclosure relates generally to pharmaceutical compositions including a muscle-specific nuclease cassette, one or more guide RNA (gRNA) cassettes, and a delivery system for the muscle-specific nuclease cassette and the one or more gRNA cassettes. The pharmaceutic composition may also include a normal or mutation-corrected DNA template carrying a modification to be made in a target nucleic acid sequence (e.g., a homology template). The present disclosure also relates to methods for treating a subject having a muscular or neuromuscular disorder. In particular, the methods may include administering to the subject a therapeutically effective amount of the pharmaceutical composition. The present disclosure also relates to methods of modifying or editing the sequence of a target nucleic acid sequence in a muscle cell and/or a muscle progenitor cell. The methods may include contacting or transducing the muscle cell and/or the muscle progenitor cell with a muscle-specific nuclease cassette and one or more gRNA cassettes. The methods may also include contacting or transducing the muscle cell and/or the muscle progenitor cell with a mutation-corrected DNA template including a modification to be made in the target nucleic acid sequence. The muscle-specific nuclease cassette, the one or more gRNA cassettes, and/or the mutation-corrected DNA template may be present on a single piece of DNA or on two or more pieces of DNA.
A variety of approaches for gene therapy of Duchenne muscular dystrophy (DMD) are in development, including microdystrophin delivery by adeno-associated virus (AAV) vector (see Gregorevic, P. et al., Nature Med. 10, 828-834, doi:10.1038/nm1085 (2004); Bengtsson, N. E., et al. Hum. Mol. Genet., doi:10.1093/hmg/ddv420 (2015); and Chamberlain, J. R., et al. Mol. Ther. 25, 1125-1131, http://dx.doi.org/10.1016/j.ymthe.2017.02.019 (2017)). However, microdystrophins are not fully functional and episomal AAV vectors could be gradually lost during normal myofiber turnover. An emerging, alternative strategy is to modify the dystrophin gene using the CRISPR/Cas9 system, such as has recently been shown by deletion of an exon in the mdxScSn mouse model of DMD (see Tabebordbar, M., et al. Science, doi:10.1126/science.aad5177 (2015); Nelson, C. E., et al. Science, doi: 10.1126/science. aad5143 (2015); and Long, C., et al. Science, doi:10.1126/science.aad5725 (2015)). However, strategies to apply gene editing to the dystrophin gene will require great flexibility due to its frequency (approximately 1:5000 newborn males) and the high incidence of spontaneous new mutations in this X-linked recessive disorder (see Emery, A. E. H., et al. Duchenne Muscular Dystrophy. 3rd edn, (Oxford University Press, 2003) and Mendell, J. R., et al. Annals of neurology 71, 304-313, doi:10.1002/ana.23528 (2012)). Mutations in the 2.2 megabase dystrophin gene result in loss of expression of both dystrophin and the dystrophin-glycoprotein complex, causing muscle membrane fragility and progressive muscle wasting (see Emery, A. E. H., et al. Duchenne Muscular Dystrophy. 3rd edn, (Oxford University Press, 2003) and Batchelor, C. L., et al. Trends Cell Biol. 16, 198-205, doi:10.1016/j.tcb.2006.02.001 (2006)). AAV vectors derived from serotypes 6, 8, and 9 have shown considerable promise in animal models for DMD by enabling systemic delivery of genetic cassettes that can partially compensate for the absence of dystrophin (see Gregorevic, P., et al. Nature Med. 10, 828-834, doi:10.1038/nm1085 (2004) and Bengtsson, N. E., et al. Hum. Mol. Genet., doi:10.1093/hmg/ddv420 (2015)). While AAVs do not exclusively target striated muscle, highly restricted muscle transduction can be achieved by using muscle-specific gene regulatory cassettes (see Salva, M. Z., et al. Mol. Ther. 15, 320-329, doi:10.1038/sj.mt.6300027 (2007)). An inherent limitation to AAV vector-mediated dystrophin replacement is the inability to fit the 14 kilobase (kb) cDNA into the ˜5 kb vector packaging limit. Microdystrophins that lack non-essential domains dramatically improve muscle pathophysiology in dystrophic animal models, yet do not fully restore muscle strength (see Harper, S. Q., et al. Nature Med. 8, 253-261, doi:10.1038/nm0302-253 (2002); Rahimov, F., et al. J. Cell Biol. 201, 499-510, doi:10.1083/jcb.201212142 (2013); Banks, G. B., et al. PLoS Genet. 6, e1000958, doi:10.1371/journal.pgen.1000958 (2010); and Lai, Y., et al. J. Clin. Invest. 119, 624-635, doi:10.1172/JCI36612 (2009).
The embodiments disclosed herein will become more fully apparent from the following description and appended claims, taken in conjunction with the accompanying drawings.
A pharmaceutical composition may include a muscle-specific nuclease cassette, one or more gRNA cassettes, and a delivery system for delivery of the muscle-specific nuclease cassette and the one or more gRNA cassettes. The pharmaceutical composition may also include a template sequence homologous to a target sequence (e.g., a homology template). Methods for treating a subject having a muscular or neuromuscular disorder may include administering to the subject a therapeutically effective amount of the pharmaceutical composition. Furthermore, methods of modifying or editing the sequence of a target nucleic acid sequence in a muscle cell may include contacting or transducing the muscle cell with a muscle-specific nuclease cassette, one or more gRNA cassettes, and/or a template sequence homologous to a target sequence. The one or more gRNA cassettes may encode a gRNA coding sequence and a mutation-corrected DNA template including a modification to be made in the target nucleic acid sequence. The muscle-specific nuclease cassette, the one or more gRNA cassettes, and/or the template sequence homologous to a target sequence may be carried or delivered in the same vector or in two or more separate vectors.
It will be readily understood that the embodiments, as generally described herein, are exemplary. The following more detailed description of various embodiments is not intended to limit the scope of the present disclosure, but is merely representative of various embodiments. Moreover, the order of the steps or actions of the methods disclosed herein may be changed by those skilled in the art without departing from the scope of the present disclosure. In other words, unless a specific order of steps or actions is required for proper operation of the embodiment, the order or use of specific steps or actions may be modified.
Unless specifically defined otherwise, the technical terms, as used herein, have their normal meaning as understood in the art. The following terms are specifically defined with examples for the sake of clarity.
As used herein, “a” and “an” denote one or more, unless specifically noted.
As used herein, “about” refers to a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, or length that varies by as much as about 30%, about 25%, about 20%, about 15%, about 10%, about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, about 2%, or about 1% to a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, or length. In any embodiment discussed in the context of a numerical value used in conjunction with the term “about,” it is specifically contemplated that the term “about” can be omitted.
As used herein, an “increased” or “enhanced” amount is typically a “statistically significant” amount, and may include an increase that is about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, about 2, about 2.5, about 3, about 3.5, about 4, about 4.5, about 5, about 6, about 7, about 8, about 9, about 10, about 15, about 20, about 30, about 40, about 50, or more times (e.g., about 100, about 500, about 1,000 times; including all integers and decimal points in between and above 1, e.g., 2.1, 2.2, 2.3, 2.4, etc.) an amount or level described herein. Similarly, as used herein, a “decreased,” “reduced,” or “lesser” amount is typically a “statistically significant” amount, and may include a decrease that is about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6 about 1.7, about 1.8, about 1.9, about 2, about 2.5, about 3, about 3.5, about 4, about 4.5, about 5, about 6, about 7, about 8, about 9, about 10, about 15, about 20, about 30, about 40, about 50, or more times (e.g., about 100, about 500, about 1,000 times; including all integers and decimal points in between and above 1, e.g., 3.6, 3.7. 3.8, 3.9, etc.) an amount or level described herein.
As used herein, a “subject” includes any animal that exhibits a disease or symptom, or is at risk for exhibiting a disease or symptom. Suitable subjects include laboratory animals (e.g., mice, rats, rabbits, and guinea pigs), farm animals, and domestic animals or pets (e.g., cats or dogs). Non-human primates and human patients are also included.
As used herein, a “therapeutically effective amount” or a “therapeutically effective dose” refers to an amount of a compound or pharmaceutical composition that, when administered to a subject, is sufficient to effect partial or complete treatment of a disease or condition in the subject. The amount of a compound or pharmaceutical composition that constitutes a “therapeutically effective amount” will vary depending on the compound or pharmaceutical composition, the condition and its severity, the manner of administration, and/or the age of the subject to be treated, but can be determined routinely by one of ordinary skill in the art having regard to his or her own knowledge and to this disclosure. Accordingly, when a compound or pharmaceutical composition is said to possess “therapeutic efficacy,” this is intended to mean that the compound or pharmaceutical composition is capable of effecting treatment of a disease or condition in a subject, provided a “therapeutically effective amount” of the compound or pharmaceutical composition is administered under appropriate conditions.
As used herein, “treating” or “treatment” refers to the treatment of a disease or condition of interest in a subject (e.g., a human) having the disease or condition of interest, and includes: (i) preventing or inhibiting the disease or condition from occurring in the subject, for example, when the subject is predisposed to the condition but has not yet been diagnosed as having the condition; (ii) inhibiting the disease or condition, i.e., arresting its development; (iii) relieving the disease or condition, i.e., causing regression of the disease or condition; and/or (iv) relieving the symptoms resulting from the disease or condition.
As used herein, “disease,” “disorder,” and “condition” may be used interchangeably or may be different in that the particular malady, injury, or condition may not have a known causative agent (so that etiology has not yet been determined), and it is, therefore, not yet recognized as an injury or disease but only as a condition or a syndrome (e.g., an undesirable condition or syndrome), wherein a more or less specific set of symptoms has been identified by clinicians.
The formulations can be prepared in pharmaceutically acceptable, physiologically acceptable, and/or pharmaceutical-grade solutions for administration to a cell or a subject (e.g., an animal), either alone, or in combination with one or more other modalities of therapy. The formulations may be administered in combination with other agents, such as other proteins, polypeptides, pharmaceutically active agents, etc.
The compositions can be administered via any suitable route, including but not limited to, locally, orally, subcutaneously, systemically, intravenously, intravascularly, intramuscularly, mucosally, transdermally (e.g., via a patch), or via a bolus. Accordingly, in addition to these general routes of administration, in some embodiments, the composition may be administered via a mode selected from the group consisting of, but not limited to: parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intratumoral, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intravaginal, buccal, sublingual, and intranasal, and via administration to the central nervous system. The compositions may be encapsulated in liposomes, exosomes, microparticles, microcapsules, nanoparticles, and the like. Techniques for formulating and administering therapeutically useful polypeptides are also disclosed in Remington: The Science and Practice of Pharmacy (Alfonso R. Gennaro, et al. eds. Philadelphia College of Pharmacy and Science 2000), which is incorporated herein in its entirety.
In some embodiments, the compositions of the present disclosure may be administered via a schedule including continuous administration or intermittent administration. Accordingly, in addition to these general schedules, in some embodiments, the composition may be administered twice a day, once a day, once every other day, once a week, once a month, or another suitable period of administration.
Microdystrophins, which lack non-essential domains, are not fully functional and in some cases do not fully restore muscle strength. This deficit may be overcome in some mutational contexts (e.g., in the case of small mutations such as point mutations or small deletions that do not remove essential dystrophin gene exons) using the CRISPR/Cas9 system to modify or correct the mutated dystrophin gene in vivo. The potential of this system has previously been demonstrated in patient-derived iPSCs and murine germline manipulation studies (see Li, H. L., et al. Stem Cell Rep., doi:10.1016/j.stemcr.2014.10.013 (2014) and Long, C., et al. Science 345, 1184-1188, doi:10.1126/science.1254445 (2014)). Studies have also utilized the CRISPR/Cas9 system for in vivo excision of dystrophin exon 23 (see Tabebordbar, M., et al. Science, doi:10.1126/science.aad5177 (2015); Nelson, C. E., et al. Science, doi: 10.1126/science. aad5143 (2015); and Long, C., et al. Science, doi:10.1126/science.aad5725 (2015)), which carries a nonsense mutation in the mdxScSn mouse [see Sicinski, P., et al. Science 244, 1578-1580 (1989)]. As DMD is a new mutation syndrome and more than 4,000 independent mutations have been identified (see http://www_dmd_nl), it has been explored whether alternative gene editing strategies may be developed for more complex mutational contexts. The present disclosure utilized the mdx4cv mouse model that harbors a nonsense mutation within exon 53 (see Im, W. B., et al. Hum. Mol. Genet. 5, 1149-1153 (1996)). Notably, this is homologous to human exon 53 which is within a mutational hot spot region that carries the genetic lesion in ˜60% of patients with DMD-causing deletions (see Flanigan, K. M., et al. Human mutation 30, 1657-1666, doi: 10.1002/humu.21114 (2009)). The mdx4cv model exhibits fewer dystrophin-revertant myofibers than the original mdxScSn strain and a slightly more progressive phenotype, thus providing a more representative model of DMD. In contrast to exon 23, excision of exon 53 will not restore an open-reading frame (ORF) to the resulting mRNA, therefore a much larger genomic region containing both exons 52 and 53 must be removed or the mutation itself directly targeted. Editing different regions of the vast dystrophin gene could generate very different results as the effects on pre-mRNA splicing and the stability and/or functional properties of modified dystrophins are generally not always predictable (see Harper, S. Q., et al. Nature Med. 8, 253-261, doi:10.1038/nm0302-253 (2002)).
Gene replacement therapies utilizing adeno-associated viral (AAV) vectors hold promise for treating Duchenne muscular dystrophy (DMD). A potentially longer-lasting approach revolves around efforts to directly modify the dystrophin gene using the CRISPR/Cas9 system. Here multiple approaches are provided for editing the mutation in the mdx4cv mouse model for DMD using both single- and dual-AAV vector delivery of a muscle-specific Cas9 cassette together with single-guide RNA cassettes and, in one approach, a dystrophin homology region. Muscle-restricted Cas9 expression was able to lead to direct gene editing of the mutation, multi-exon deletion or complete gene correction via homologous recombination in post-mitotic myofibers. Treated muscles demonstrated production of near- to full-length dystrophin in up to 70% of the myogenic cross-sectional area and a significant increase in force generation.
Induction of dystrophin expression was tested following AAV6-mediated delivery of CRISPR/Cas9 components derived from either Streptococcus pyogenes (SpCas9) (see Cong, L., et al. Science 339, 819-823 (2013)) or Staphylococcus aureus (SaCas9) (see Ran, F. A., et al. Nature 520, 186-191 (2015)) using dual- or single-vector approaches, respectively (see
The overall approaches used in strategy 1 (Δ5253) are potentially applicable to a majority of DMD patients with mutations affecting one or more exons whose removal via editing would allow production of an mRNA with an ORF. For this, sgRNAs were designed to direct Cas9-mediated DNA cleavage within the introns flanking exons 52-53 (see
Dystrophin gene targeting was initially evaluated in vitro using the T7 endonuclease 1 assay in mdx4cv-derived primary dermal fibroblasts. The respective targeting efficiencies for sgRNA-i51 and sgRNA-i53 were 9 and 16%, while a combined targeting efficiency of 8% was observed for the 5′ and 3′ sgRNAs within exon 53 (which due to their close proximity were analyzed together (see
Table 1 depicts deep sequencing quantification of editing efficiency and HDR events using CRISPRESSO™. Efficient targeting was observed at all target sites for the different approaches. For NHEJ events, the majority of edited reads corresponded to deletions followed by insertions and substitutions (see
For strategy 2, the combined gene editing efficiency for both target sites within exon 53 was 2.3%, as determined by deep sequencing (see
Establishment of a functional ORF led to significant induction of dystrophin expression in treated TAs as detected by immunostaining of muscle cryosections (see
Immunostaining of muscle cross-sections revealed that an average of 41 (Δ5253) and 45% (53*) of myofibers expressed dystrophin (see
Induction of dystrophin expression also allowed for sarcolemmal localization of neuronal nitric oxide synthase (nNOS), an important component of the dystrophin-glycoprotein complex that modulates muscle performance (see
On the basis of the higher dystrophin-correction efficiency observed for strategy 1, this approach was tested following systemic delivery of the AAV nuclease and targeting vectors using a range of doses between 1-10×1012 v.g. per mouse. Both single- and dual-vector approaches yielded widespread dystrophin expression in the heart, with up to 34% of cardiac myofibers expressing dystrophin at 4 weeks post-transduction (see
The results provided herein demonstrate that muscle-specific CRISPR/Cas9-mediated gene editing is effective in inducing dystrophin expression in dystrophic mdx4cv mouse muscles. Localization of dystrophin-associated proteins, such as nNOS, to the sarcolemma and increased muscle force generation was also observed. Restriction of Cas9 expression to myogenic cells offers several advantages over ubiquitous expression by preventing expression of the bacterial Cas9 nuclease in non-muscle (including immune effector) cells and eliminating the impact of possible off-target events affecting genes expressed in mitotically active non-muscle cells, such as hepatocytes. Although HDR is believed to occur infrequently in post-mitotic tissues, at least a fraction of myogenic cells in dystrophic muscles displayed successful HDR-mediated gene correction following CRISPR/Cas9 delivery, as demonstrated by the presence of HDR-derived transcripts. Whether targeting of post-mitotic myonuclei or proliferating myogenic progenitors is responsible for these HDR events is currently unclear. However, MCK regulatory regions are not transcriptionally active in satellite cells or proliferating myoblasts (see Hu, C., et al. Mol. Ther. 22, 1792-1802 (2014); Chamberlain, J. S., et al. Mol. Cell. Biol. 5, 484-492 (1985); Jaynes, J. B., et al. Mol. Cell. Biol. 6, 2855-2864 (1986); and Hauser, M. A., et al. Mol. Ther. 2, 16-25 (2000)). In this regard, it was previously shown that homologous recombination between separate AAV vector genomes occurs at a moderate frequency in post-mitotic mouse myofibers (see Odom, G. L., et al. Mol. Ther. 19, 36-45 (2011)). Further improvements to HDR-based gene editing strategies could possibly be achieved by inhibiting genes involved in NHEJ, which may increase the efficiency of precise gene editing if the HDR events were occurring in mitotically active myogenic precursors (see Maruyama, T., et al. Nat. Biotechnol. 33, 538-542 (2015)), and/or via the use of alternative CRISPR associated nucleases (such as Cpf1 or Cas9-nickase) (see Zetsche, B., et al. Cell 163, 759-771 (2015) and Ran, F. A., et al. Cell 154, 1380-1389 (2013)).
For excision of exons 52-53, both single- and dual-vector approaches were able to induce dystrophin expression with similar efficiencies, despite an apparent higher frequency of editing with the dual vectors. It is possible that the difference in overall gene editing efficiency stems from a difference in the propensity for indel formation between SpCas9 and SaCas9 following DNA cleavage at the chosen target sites. For instances when DNA cleavage did not result in deletion of the intervening 45 kb segment, SpCas9 may have generated indels at the cut sites at higher frequencies than SaCas9, resulting in a perceived higher editing efficiency. Actual deletion of the intervening sequence may in fact have been comparable, which the downstream (mRNA and protein) data reflect. Nevertheless, a dual-vector approach may currently offer more flexibility in terms of allowing for variations in the ratio between administered nuclease versus targeting components, which may prove important for efficiency. If efficient transduction of myogenic stem cells (satellite cells) can be achieved in vivo, dystrophin correction could be permanent by ensuring continued generation of dystrophin expressing myofibers during normal muscle turnover. While previous results indicated that satellite cell transduction using AAV6, 8, or 9 is very low compared with myofibers (see Arnett, A. L. H., et al., Mol. Ther. Methods Clin. Dev. 1, 14038 (2014)), one other group found that AAV9 was able to target these stem cells with modest efficiency (see Tabebordbar, M., et al. Science 351, 407-411 (2016)). The reasons for these differing results are unclear, but significantly greater targeting efficiencies will likely be needed to support long-term regeneration from corrected myogenic stem cells. While the CK8 regulatory cassette in conjunction with CRISPR/Cas9 gene editing is clearly useful for correcting dystrophin mutations in myofibers, CK8 activity in satellite cells or proliferating myoblasts has not been observed (see Himeda, C. L., et al. Methods Mol. Biol. 709, 3-19 (2011) and Arnett, A. L. H., et al. Mol. Ther. Methods Clin. Dev. 1, 14038 (2014)).
Immunofluorescent, DNA, and protein analyses at 12 weeks post systemic delivery of varying doses (A-D) of dual rAAV6 vectors consisting of a nuclease vector expressing SaCas9 under control of the muscle-specific CK8e promoter and a targeting vector (Δ5253) are depicted in
An overview of the HDR strategy provided herein is depicted in
Analysis of gene editing efficiency and successful HDR at 4 weeks post-treatment is depicted in
A first aspect of the disclosure relates to pharmaceutical or biopharmaceutical compositions. The pharmaceutical composition may include a muscle-specific nuclease cassette, one or more gRNA cassettes (e.g., a first gRNA cassette), and/or a mutation-corrected homology template (e.g., for HDR) and a delivery system for delivery of the muscle-specific nuclease cassette, the gRNA cassette(s), and/or the mutation-corrected homology template.
In some embodiments, the muscle-specific nuclease cassette may include a muscle-specific transcriptional regulatory cassette and a nuclease coding sequence. The nuclease coding sequence may encode a CRISPR-associated nuclease. For example, the nuclease coding sequence may encode a protein selected from SaCas9, SpCas9, Cpf1, or another suitable CRISPR-associated nuclease.
In some embodiments, the muscle-specific transcriptional regulatory cassette may be derived from an M-creatine kinase enhancer and/or a M-creatine kinase promoter sequence. For example, the muscle-specific transcriptional regulatory cassette may be derived from a M-creatine kinase enhancer plus a M-creatine kinase promoter. Furthermore, the muscle-specific transcriptional regulatory cassette may include one or more enhancers derived from conserved regions of muscle creatine kinase and/or a CK8 transcriptional regulatory cassette (SEQ ID NO:159).
The muscle-specific transcriptional regulatory cassette may be a muscle-specific CK8 transcriptional regulatory cassette (CK8). CK8 is a non-naturally occurring nucleotide sequence including multiple muscle and non-muscle gene control elements arranged in a miniaturized array. CK8 may provide high or very high transcriptional expression of a predetermined RNA and/or protein in skeletal and cardiac muscle cells.
In certain embodiments, the muscle-specific transcriptional regulatory cassette may be a CK8 transcriptional regulatory cassette. The CK8 transcriptional regulatory cassette may have at least 70% sequence identity, at least 80% sequence identity, at least 85% sequence identity, at least 90% sequence identity, at least 91% sequence identity, at least 92% sequence identity, at least 93% sequence identity, at least 94% sequence identity, at least 95% sequence identity, at least 96% sequence identity, at least 97% sequence identity, at least 98% sequence identity, at least 99% sequence identity, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO:159.
In various embodiments, the muscle-specific transcriptional regulatory cassette may express the nuclease coding sequence such that a level of expression of the nuclease coding sequence is at least 50-fold higher, at least 75-fold higher, at least 100-fold higher, or at least 150-fold higher in muscle cells than the level of expression of the nuclease coding sequence in non-muscle cells.
The pharmaceutical composition may further include a second gRNA cassette, wherein the first gRNA cassette includes a first gRNA coding sequence and the second gRNA cassette includes a second gRNA coding sequence. In some other embodiments, the pharmaceutical composition may further include three or more gRNA cassettes. For example, the pharmaceutical composition may further include: a third gRNA cassette, wherein the third gRNA cassette includes a third gRNA coding sequence; a fourth gRNA cassette, wherein the fourth gRNA cassette includes a fourth gRNA coding sequence; and so on.
In certain embodiments, the pharmaceutical composition may further include a mutation-corrected DNA template, wherein the mutation-corrected DNA template is configured for HDR. The muscle-specific transcriptional regulatory cassette and/or the gRNA cassettes described above may also include such a mutation-corrected DNA template (or the mutation-corrected DNA template may be delivered separately from the muscle-specific transcriptional regulatory cassette and/or the gRNA cassettes), wherein the mutation-corrected DNA template may be configured for HDR. The mutation-corrected DNA template may be configured to repair a mutated target nucleic acid sequence. In some embodiments, the mutated target nucleic acid sequence may be in a gene associated with a neuromuscular disorder. For example, the mutated target nucleic acid sequence may be in a gene encoding dystrophin.
In some embodiments, the delivery system can include a recombinant adeno-associated virus (rAAV) vector. For example, the rAAV vector may be an rAAV6 vector, an rAAV8, an rAAV9 vector, or another suitable rAAV vector. In various embodiments, the rAAV vector may be an rAAV6 vector. The delivery system may include a single rAAV vector to deliver the muscle-specific nuclease cassette and the one or more gRNA cassettes. Alternatively, the delivery system may include a first rAAV vector to deliver the muscle-specific nuclease cassette and a second rAAV vector to deliver the one or more gRNA cassettes. Furthermore, the delivery system may include a third rAAV vector to deliver an additional gRNA cassette, a fourth rAAV vector to deliver an additional gRNA cassette, and so on. Any of these rAAV vectors may include a mutation-corrected DNA template configured for HDR.
The pharmaceutical composition may reduce a pathological effect or symptom of a neuromuscular disorder in a subject. In various embodiments, the pharmaceutical composition may increase a specific-force generating capacity of at least one skeletal muscle in a subject to within at least 25%, at least 30%, at least 40%, or at least 50% of a normal specific-force generating capacity in a skeletal muscle. In some embodiments, the pharmaceutical composition may restore a baseline end-diastolic volume defect in a subject to within at least 25%, at least 30%, at least 40%, or at least 50% of a normal end-diastolic volume.
The pathological effect or symptom of the neuromuscular disorder may be selected from at least one of muscle pain, muscle weakness, muscle fatigue, muscle atrophy, fibrosis, adipose cell accumulation, inflammation, increase or decrease in average myofiber diameter in skeletal muscle, centrally-nucleated myofiber number, cardiomyopathy, reduced 6-minute walk test time, loss of ambulation, and cardiac pump failure.
The neuromuscular disorder may be a muscular dystrophy selected from at least one of myotonic muscular dystrophy (DM1 and/or DM2), Duchenne muscular dystrophy, Becker muscular dystrophy, any of the various types of limb-girdle muscular dystrophy, facioscapulohumeral muscular dystrophy, any of the various types of congenital muscular dystrophy, oculopharyngeal muscular dystrophy, distal muscular dystrophy, desmin-related myopathies, fukyama muscular dystrophy, FKRP-deficiencies and Emery-Dreifuss muscular dystrophy. In some embodiments, the muscular dystrophy may be Duchenne muscular dystrophy.
Another aspect of the disclosure relates to methods for treating a subject having a neuromuscular disorder. In certain embodiments, the method may include administering to the subject a therapeutically effective amount of a pharmaceutical composition. The pharmaceutical composition may include a muscle-specific nuclease cassette and one or more gRNA cassettes and/or a mutation corrected template for HDR. The pharmaceutical composition may further include a delivery system for delivery of the muscle-specific nuclease cassette, the one or more gRNA cassettes, and/or the mutation-corrected DNA template configured for HDR.
In various embodiments, the therapeutically effective amount of the pharmaceutical composition may be between about 1011 and about 1016 vector genomes (vg)/kilogram (kg) subject weight, between about 1012 and about 1015 vg/kg subject weight, between about 1013 and about 1014 vg/kg subject weight, or another suitable amount. In some embodiments, the pharmaceutical composition may be administered intravascularly, intraperitoneally, subcutaneously, or orally. In certain embodiments, the pharmaceutical composition may include no, up to 5%, up to 10%, up to 20%, up to 30%, up to 40%, up to 50%, up to 60%, up to 70%, up to 80%, or up to 90% empty capsids (see U.S. Pat. No. 7,655,467 and European Patent No. 1689230).
Another aspect of the disclosure relates to methods of modifying the sequence of a target nucleic acid sequence in a muscle cell or a myogenic progenitor cell. In certain embodiments, the method may include contacting or transducing the muscle cell or the myogenic progenitor cell with a delivery system and/or the contents of the delivery system. The delivery system may include a muscle-specific nuclease cassette, one or more gRNA cassettes, and/or a mutation-corrected DNA template comprising a modification to be made in the target nucleic acid sequence (i.e., a homology template for HDR).
In certain embodiments, the method may include inducing expression of a gene associated with a neuromuscular disorder in the muscle cell. For example, the method may include inducing expression of dystrophin in the muscle cell.
The following examples are illustrative of disclosed methods and compositions. In light of this disclosure, those of skill in the art will recognize that variations of these examples and other examples of the disclosed methods and compositions would be possible without undue experimentation.
Plasmids containing regulatory cassettes for expression of Cas9 or gRNAs flanked by AAV serotype 2 inverted terminal repeats (ITRs) were generated using standard cloning techniques. The spCas9 nuclease expression cassette was generated by PCR cloning of NLS-SpCas9-NLS from LentiCRISPRv1 (see Shalem, O., et al. Science 343, 84-87 (2014)), and insertion into pAAV (STRATAGENE™) containing the ubiquitous elongation factor-1 alpha short promoter (EFS) (id.) (for in vitro studies in fibroblasts) or the muscle-specific creatine kinase 8 (CK8) regulatory cassette (RC) (see Himeda, C. L., et al. Methods Mol. Biol. 709, 3-19 (2011) and Hu, C., et al. Mol. Ther. 22, 1792-1802 (2014)) (for in vivo studies). (Sp)sgRNA target sequences were selected using the online software ZIFIT TARGETER™ (http://zifit_partners_org/ZiFiT/) and inserted into pLentiCRISPRv1 following BsmB1 restriction enzyme digestion. Two targeting constructs to work in conjunction with SpCas9 were generated by PCR cloning of the U6-(Sp)sgRNA expression cassette from pLentiCRISPRv1 followed by insertion into pAAV plasmids on either side of a CMV-mCherry expression cassette and a HDR template spanning positions X84575274 to X84576081 of the murine DMD gene cloned from C57BL/6 genomic DNA. The corresponding protospacer adjacent motif (PAM) sites at positions X84575612 (G-A) and X84575639 (G-A) within the HDR template were mutated using PCR-mediated mutagenesis while preserving the encoded amino acids (silent mutations) to eliminate or reduce targeting of the DNA repair template by Cas9. The modified HDR sequence, gRNA sequences as well as primer sequences for cloning and PCR amplification of genomic DNA and complementary DNA (cDNA) are provided in
Primary dermal fibroblasts were isolated from 3-week-old male mdx4cv mice (see Takashima, A. Curr. Protoc. Cell Biol. 2.1, 2.1.1-2.1.12 (2001)). Electroporation of ˜600,000 cells per strategy were performed in INVITROGEN™ R-buffer containing 4 μg of both nuclease (EFS-SpCas9) and targeting (Δ5253/53*) plasmid expression constructs using a NEON® transfection system (INVITROGEN™) with three 10 ms pulses of 1,650 volts. Cells were subsequently seeded on 0.1% gelatin-coated culture vessels and maintained for 12 days in Dulbecco's modified Eagle medium supplemented with Penicillin-Streptomycin, Sodium pyruvate, L-Glutamine and 15% fetal bovine serum (THERMO FISHER SCIENTIFIC™) before harvest and DNA isolation (DNEASY° , QIAGEN™)
All animal experiments were approved by the Institutional Animal Care and Use Committee of the University of Washington. Intramuscular delivery of 2.5-5×1010 v.g. of each vector (nuclease and targeting) was performed via longitudinal injection into tibialis anterior (TA) muscles of 2-12-week-old male C57BL/6-mdx4cv (mdx4cv) mice. For strategy 1, systemic delivery of 1×1012 v.g. (low dose) to 1×1013 v.g. (high dose) was performed via retro-orbital injection into 11 week-old male mdx4cv mice (n=3). Both dual- and single-vector approaches were evaluated at the low dose of 1×1012 v.g. of each vector, while the dual-vector approach was also evaluated at a high dose of 1×1013 v.g. of the nuclease vector and 4×1012 v.g. of the targeting vector. The mdx4cv mouse model of DMD harbors a nonsense C to T mutation in exon 53 leading to a loss of dystrophin expression (see Im, W. B., et al. Hum. Mol. Genet. 5, 1149-1153 (1996)). These mice exhibit ˜10-fold lower frequencies of revertant dystrophin expressing muscle fibers than the original mdxscsn mouse strain, which provides much greater assurance that dystrophin-corrected fibers resulted from gene targeting rather than spontaneous reversion.
Muscles were collected and analyzed at 4 weeks post-transduction and compared with age-matched male non-injected mdx4cv and WT mice, except for mice undergoing physiological measurements which were analyzed at 18 weeks post-transduction. Medial portions of TA muscles were embedded in Optimal Cutting Temperature (O.C.T.) compound (VWR® International) and fresh frozen in liquid nitrogen cooled isopentane for immunofluorescence analysis. The remaining portions of TA muscles were snap frozen in liquid nitrogen and ground to a powder under liquid nitrogen in a mortar kept on dry ice for subsequent extraction of DNA, RNA, and protein.
TA cross-sections (10 μm) were co-stained with antibodies raised against alpha 2-laminin (SIGMA®, rat monoclonal, 1:200) and the C-terminal domain of dystrophin (from Dr. Stanley Froehner at the University of Washington, Department of Physiology and Biophysics, rabbit polyclonal, 1:500). Serial sections were stained with antibodies raised against neuronal nitric oxide synthase (INVITROGEN™, rabbit polyclonal, 1:200). Slides were mounted using PROLONG® Gold with DAPI (THERMO FISHER SCIENTIFIC™) and imaged via LEICA™ SPV confocal microscope at the University of Washington Biology Imaging Facility (http://depts_washington_edu/if/). Confocal micrographs covering the entirety of injected TA muscle sections were acquired and montaged using the FIJI™ toolset (IMAGEJ™) and PHOTOSHOP® (ADOBE™). Quantification of dystrophin-positive myofibers and dystrophin-positive muscle cross-sectional area was performed via semi-automated tracing and measurement of 1,250 to 3,500 individual myofibers per TA using ADOBE PHOTOSHOP® (n=5 TAs per treatment group). Automated quantification of central nucleation was performed using software developed in-house by Rainer Ng (CHAMP) running on the MATLAB™ platform.
DNA and RNA were isolated using TRIZOL® reagent (INVITROGEN™) according to the manufacturer's recommendations. Approximately 500 bp amplicons across the targeted regions of genomic DNA were generated by PCR using PHUSION® proof-reading polymerase (NEW ENGLAND BIOLABS®) and analyzed for targeting efficiency using T7 endonuclease 1 (NEW ENGLAND BIOLABS®), next generation sequencing (BGI™ International or in-house) or Sanger sequencing (SIMPLESEQ™, EUROFINS™ MWG Operon) of subclones of PCR amplicons (ZERO BLUNT™ TOPO™, INVITROGEN™). The T7 endonuclease assay was performed by denaturing and re-annealing the amplified PCR product followed by treatment with T7 endonuclease 1 to cleave indel-derived heteroduplex PCR products. Analysis of dystrophin-targeted transcripts by RT-PCR of the target regions was performed on cDNA made using SUPERSCRIPT® III first-strand synthesis superm ix (INVITROGEN™). Specific indel mutations or deletions in the dystrophin transcript were identified by Sanger sequencing of individual subclones of RT-PCR fragments. Muscle proteins were extracted in radioimmunoprecipitation analysis buffer (RIPA) supplemented with 5 mM EDTA and 3% protease inhibitor cocktail (SIGMA®, Cat #P8340), for 1 hour on ice with gentle agitation every 15 minutes. Total protein concentration was determined using PIERCE™ BCA assay kit (THERMO FISHER SCIENTIFIC™). Muscle lysates from WT (10 and 1 μg), untreated mdx4cv (30 μg), and treated mdx4cv (30 μg) mice were denatured at 99 degrees Celsius for 10 minutes, quenched on ice and separated via gel electrophoresis after loading onto BOLT™ 4-12% Bis-Tris polyacrylamide gels (INVITROGEN™). Protein transfer to 0.45 μm PVDF membranes was performed overnight at constant 34 volts at 4 degrees Celsius in Towbin buffer containing 20% methanol. Blots were blocked for 1 hour at room temperature in 5% non-fat dry milk before overnight incubation with antibodies raised against the C-terminal domain of dystrophin (Froehner Lab, Rabbit polyclonal, 1:10,000), anti-SpCas9 (MILLIPORE™, mouse monoclonal, 1:2,000), anti-HA (ROCHE™, Rat monoclonal-HRP conjugated, 1:2,000) for detection of HA-tagged saCas9 and GAPDH (SIGMA®, Rabbit polyclonal, 1:100,000). Horseradish-peroxidase conjugated secondary antibody staining (1:50,000) was performed for 1 hour at room temperature before signal development using CLARITY™ Western ECL substrate (BIORAD™) and visualization using a CHEMIDOC™ MP imaging system (BIORAD™) Gel- and blot-band densitometry measurements were performed on unsaturated images using IMAGEJ™ software (National Institutes of Health).
Approximately 200-250 bp PCR products were generated across target, and the top predicted off-target sites for each sgRNA using PLATINUM® Taq High-Fidelity polymerase (INVITROGEN™) or PHUSION® High-Fidelity Polymerase (NEW ENGLAND BIOLABS®). Potential off-target sites were identified using ZIFIT TARGETER™ software for SpCas9. CRISPR Rgen tools Cas-OFFinder software (http://www_rgenome_net/cas-offinder/) was used to identify potential off-target sites for SaCas9, using a mismatch number of ≦3, DNA bulge size ≦1 and RNA bulge size ≦1 For Strategy B, genomic deep sequencing was performed on a ˜230 bp nested PCR product generated from an initial ˜500 bp product amplified across exon spanning both target sites. To eliminate false detection of the HDR template DNA present in AAV vectors, the primer pair used to generate the 500 bp product was designed with one primer annealing outside of the region complimentary to the HDR template. The resulting PCR product was isolated following gel electrophoresis (GENEJET™ gel extraction kit, THERMO FISHER SCIENTIFIC™ ) before performing nested PCR followed by a second gel extraction. For each site analyzed, amplicons from 4-5 mice were pooled and subjected to standard ILLUMINA® library preparation (A-tailing, adaptor ligation, and amplification using NEBNEXT® library preparation kit (NEW ENGLAND BIOLABS®)), and QC'd using a BIOANALYZER™ before paired end (PE150) sequencing on an ILLUMINA® MISEQ™ system)(ILLUMINA® . Libraries were barcoded for multiplexed sequencing and subsequent reads were parsed and QC'd using custom scripts (TRIM GALORE™ software (http://www_bioinformatics_babraham_ac_uk/projects/trim_galore/), phred33 score≧30) and standard ILLUMINA® tools. On-target paired end (PE150) sequencing of DNA amplicons generated from muscles treated according to strategy 2 (53*) was performed by submitting the samples to BGI™ International (BGI™ AMERICAS). Uniquely mapping read pairs were used for downstream analysis using the CRISPRESSO™ software pipeline (see Pinello, L., et al. Nat. Biotechnol. 34, 695-697 (2016)). For CRISPRESSO™ analyses: 25 by at each end of the amplicon were excluded from quantification, the window size around each cleavage site used to quantify NHEJ events was set to 5 bp and sequence homology for an HDR occurrence was set to 98%. Following CRISPRESSO™ analysis, manual analysis and quantification was performed by searching for defined sequences in the quality-filtered and adapter-trimmed deep sequencing FASTQ files to provide further information on specific genotypes generated by strategy 2. For DNA reads, search sequences were chosen to span the region containing both target sites and the site of the C-T mutation. For RNA reads, search sequences were defined to span a region starting from within exon 52 (>45 kb away from the target region) extending past the prototypical cut site at the 3′ end of the target region.
Data values are represented as mean±s.e.m. and were analyzed in EXCEL™ (MICROSOFT™) and PRISM6™ (GRAPHPAD™). Measurements were analyzed for statistical significance using one-way analysis of variance (ANOVA) multiple comparison tests with Turkey's post hoc tests unless otherwise stated. Statistical significance was set to P<0.05.
The gene editing efficiency of SpCas9, SaCas9, and the new “HF” Cas9 can be compared. Efficiency can be assessed by injecting 12-week-old male mdx4cv mouse TA muscles IM, and analyzing mice 1 and 2 months later. Each Cas9 vector can be co-delivered with a vector expressing single guide RNA expression cassettes (sgRNAs) targeting: a) introns 51 and 53 (to delete exons 52-53, a 45 kb genomic interval); b) the region adjacent to the mdx4cv mutation (for NHEJ); or c) two regions flanking the mdx4cv mutation along with a homology template (to measure HDR). Efficiency can be measured by deep sequencing of: a) PCR products spanning the targeted regions; b) RT-PCR products spanning exons 51-55; and c) western blot analysis and immunostaining of injected muscles.
Off target cleavage can be assessed in the five regions with closest sequence similarity to the target sites by deep sequencing. 5×1010 vector (vg) of the AAV6/CK8-nuclease and targeting vectors in a volume of 30 μl can be injected into eight TAs per time point (contralateral muscles can serve as the negative controls). The primary end points can be the percent positive myofibers in TAs, total dystrophin expression by western blot using previously described N- and C-terminal antibodies (Bengtsson, N. E., et al. Nat. Comm., 8, 14454, doi:10.1038/ncomms14454 (2017)), assembly of the DGC by immunostaining with commercial antibodies or those supplied by Stan Froehner (Bengtsson, N. E., et al. Nat. Comm., 8, 14454, doi:10.1038/ncomms14454 (2017)), and percent corrected dystrophin gene and mRNA. DGC expression can focus on nNOS and representative DGC members, β-dystroglycan, β-sarcoglycan, α1-syntrophin, and α-dystrobrevin-2. The goal can be to determine the relative efficiency of SpCas9, SaCas9, and the newer SpCas9-HF1 in muscle.
Systemic delivery studies can be performed using retro-orbital (RO) injection into 2-month-old mdx4cv mice. Here, two enzymes can be compared, the HF1 enzyme and either the Sp or SaCas9, depending on which works best by IM. Methods can be as discussed above, at a moderate dose of 2×1012 vg/25 g mouse weight of each vector, N=8 mice. Although the smaller SaCas9 and the sgRNAs fit into a single vector they can be split into two vectors as with SpCas9 and SpCas9-HF to maintain a constant vector particle number and for varying the ratios of the components. This dose is below the maximal gene delivery using conventional AAV vectors (such as microdystrophin), but as a non-saturating dose it can facilitate identifying efficiency differences. Analysis can be on skeletal muscles (e.g., TA, gastrocnemius, soleus, and diaphragm), the heart, and in select non-muscle tissues. Time points can be two and four months post-injection. As above, these comparisons can use CK8 to drive Cas9 expression. Endpoints can include dystrophin and DGC expression, genomic DNA targeting efficiencies, and off-target editing at the 5 regions closest in sequence to the sgRNA sequences.
Off target effects in non-muscle tissues may be undetectable due to the CK8 RC, but liver and kidney may be analyzed, which are targeted well by most AAV serotypes, including AAV6 (Gregorevic, P., et al. Nature Med. 10, 828-834, doi: 10.1038/nm 1085 (2004)).
Gene editing in the original mdx mouse has been conducted using the CMV promoter (see Tabebordbar, M., et al. Science, doi:10.1126/science.aad5177 (2015); Nelson, C. E., et al. Science, doi:10.1126/science.aad5143 (2015); and Long, C., et al. Science, doi:10.1126/science.aad5725 (2015)). CMV is active in non-muscle and immune effector cells, and was used in a clinical trial that led to a dystrophin immune response (Mendell J. R. et al. N. Engl. J. Med., 363, 1429-1437 (2010)). CK RCs have been optimized for high-level expression (20-80% of CMV) in various striated muscles (see Hauser M. A., et al. Mol. Ther. 2, 16-25 (2000); Salva, M. Z., et al. Mol. Ther. 15, 320-329 (2007); Himeda, C. L., et al. Methods Mol. Biol. 709, 3-19 (2011)). However, there could be advantages in using weaker promoters for Cas9. Some studies have been performed using the relatively weak EFS promoter, but poor editing efficiencies were seen (not shown). Here, a two-month time point (N=8 mice) can be used using the weaker CK6 RC and dystrophin expression and editing can be monitored in the muscles discussed above (Hauser, 2000). The simplest strategy of deleting exons 52-53 can be tested.
Combining Cas9 and sgRNAs into a single vector can be convenient but it locks in a ratio of enzyme to sgRNAs that may not be optimal. Using two vectors can allow one to vary the ratios of the components. The vector pairs can be injected RO into 12-week mdx4cv mice using the most efficient Cas9 enzyme from the studies above (N=8/group). A constant total vector dose can be used (up to 4×1013 vg/25 g mouse), but 5 ratios may be tested, Cas9:sgRNA vector at 1:9; 2.5:7.5, 5:5, 7.5:2.5, and 9:1. 8 weeks post-injection, dystrophin and editing efficiencies (as above) can be analyzed. If the ratio of Cas9 to sgRNA proves important, the idea of testing regulatory cassettes with stronger/weaker activity to enable adjusting the ratios within a single vector can be revisited.
The optimal ratio of vectors can then be used for systemic delivery in a dose escalation study. Vector doses of 4, 8, and 12×1012 vg/25 gram mouse weight, which is approaching the upper limit of delivery due to titer, volume and vector solubility concerns can be tested. N=8 mice/dose, and editing efficiencies, dystrophin, and DGC expression can be measured at 8 and 16-weeks post-injection.
The above studies can use 12-week-old (young adult) mice so as to impact the dystrophic phenotype in an already dystrophic animal. Also, mdx and mdx4cv mice display an unusual wave of necrosis and regeneration from ˜4-10 weeks of age, a feature not shared by patients. This necrosis leads to significant loss of AAV vectors before gene expression peaks, since AAV vectors don't display optimal gene expression for ˜4 weeks, (see, e.g., Blankinship, 2004). However, gene editing efficiencies may be higher in younger mice than in adults. Therefore, at least one test can be performed in two-week old mice to compare with the results in 12-week mice. Here, the optimal parameters from the above studies can be tested by vector infusion into 2-week-old mdx4cv mice (N=8), with analysis of editing and dystrophic production conducted 8 weeks later. Preliminary studies used mice at both 2 and 8-12 weeks of age and obvious differences were not observed, but those studies were pilot in nature and not well powered. Using an N=8 should provide sufficient statistical data to compare with the studies described above.
An extensive set of morphological and functional assays of dystrophic muscle function, including muscle and myofiber cross sectional area, central nucleation, blood chemistries, specific force and susceptibility to contraction-induced injury (in TA, gastrocnemius, EDL, soleus, and diaphragm); hemodynamic assays of cardiac function, and whole animal assays such as treadmill running, fatigue, gait, and hind-limb force have been published (see, e.g., Gregorevic, P., et al. Nature Med. 10, 828-834, doi:10.1038/nm1085 (2004); Gregorevic P. et al., Nature Med. 12, 787-789 (2006); Odom G et al, Mol. Ther., 16, 1539-1545 (2008), PMC2643133.
In these assays, the optimized (from A-D) CRISPR/Cas9 vectors can be injected retro-orbitally into 12-week old mdx4cv mice (N=8/group) and analyzed for genomic and mRNA editing (by deep sequencing), dystrophin expression and pathophysiology in TA, gastrocnemius, soleus, diaphragm, and cardiac muscles at 3, 6, 12, and 24 months. Live animal assays can include cardiac Echo, hind-limb strength, fatigue, and gait. Mice may be analyzed in a blinded fashion. Other than breeders, the studies can use male mice as DMD affects males.
It will be apparent to those having skill in the art that many changes may be made to the details of the above-described embodiments without departing from the underlying principles of the invention. The scope of the present invention should, therefore, be determined only by the following claims.
This application claims the benefit of U.S. Provisional Application No. 62/352,505, filed Jun. 20, 2016, which is hereby incorporated by reference in its entirety.
This invention was made with government support under Grant No. R01 AR044533, awarded by the National Institutes of Health. The government has certain rights in the invention.
| Number | Date | Country | |
|---|---|---|---|
| 62352505 | Jun 2016 | US |
